Novel molecular pathways in Gorham disease: implications for treatment - sprookjes - yvandenbroek - TriplyDB

Novel molecular pathways in Gorham disease: implications for treatment

Novel molecular pathways in Gorham disease: implications for treatment

http://www.wikidata.org/entity/Q27005629

about

Pregnancy Complicated by Gorham-Stout Disease and Refractory Chylothorax Gorham-Stout disease of the pelvis: Seven years follow up with complete radiological evaluation.Clinical Features and Prognosis of Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, and Gorham-Stout Disease.

P2860

Q37309814-11D32580-08FB-401F-96D5-0E032AF718DB Q37384591-A87AF654-7370-4D3B-BD82-14C3D67E0235 Q40953573-14D4D732-220D-45A0-A5EE-DD3D23DA274E

P2860

Novel molecular pathways in Gorham disease: implications for treatment

http://www.wikidata.org/entity/Q27005629

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Novel molecular pathways in Gorham disease: implications for treatment

@ast

Novel molecular pathways in Gorham disease: implications for treatment

@en

Novel molecular pathways in Gorham disease: implications for treatment

@nl

type

label

Novel molecular pathways in Gorham disease: implications for treatment

@ast

Novel molecular pathways in Gorham disease: implications for treatment

@en

Novel molecular pathways in Gorham disease: implications for treatment

@nl

prefLabel

Novel molecular pathways in Gorham disease: implications for treatment

@ast

Novel molecular pathways in Gorham disease: implications for treatment

@en

Novel molecular pathways in Gorham disease: implications for treatment

@nl

P1433

Q27005629-97252C69-9C99-4B9D-8915-02233C0BCD0D

P1476

Q27005629-DCB90A7A-0F60-4B0E-A53F-D2452D2A0DBF

P2093

Q27005629-25595E59-F4FF-4C0D-8FD5-F8D2567AC8E7

Q27005629-7D633CB7-16B9-411D-8CD8-99541F485F18

Q27005629-872AB75E-417F-47C8-8617-D1F966A6F367

Q27005629-D70D94B6-E803-4E7E-A118-D9FBDD12CFA0

P2860

Q27005629-16022382-9807-4BAF-A43B-74D0A02FCA5B

Q27005629-190B16DB-973A-4273-9F04-B459F0978DAC

Q27005629-1B9D4071-4CD0-4920-B45E-6EF1395CC01B

Q27005629-292A70F6-424F-4737-A035-62027C2486C9

Q27005629-2A65C0F2-52B1-4D89-A403-15F40E31A58B

Q27005629-35917F68-ECBC-48FF-8D8A-81C0C77A8291

Q27005629-397D9FA4-78A2-4138-BF3A-B97F126B330E

Q27005629-452D28B7-6151-4DD2-9220-C441355A6D06

Q27005629-4A9D1778-A896-4E24-BA05-37846C941EA2

Q27005629-5061D175-F8B4-4EA1-B5C5-0A2DD132F96D

P304

Q27005629-99604068-669A-44CA-8BCF-B80B49BEB031

P31

Q27005629-BFF407FD-8125-419B-B0E6-8DEC1E725841

P3181

Q27005629-2B84AA1D-20FA-4549-ACE9-877D71A52428

P356

Q27005629-F5F565BB-9A44-495E-9D28-32980D00A6C8

P407

Q27005629-8A1D19E8-AAA5-4C28-A68D-962D75595F1A

P433

Q27005629-07C1D5E3-A2F8-4B05-81AD-966FDB51449C

P478

Q27005629-6339A040-C091-4951-BF43-78012980B208

P50

Q27005629-23F46A2A-30F3-4984-B9BD-E70788A00123

P577

Q27005629-81753A1B-0223-4B5C-8851-B9A8DC575D94

P5875

Q27005629-F8D05496-5ECF-4F9C-B826-04B0F2F26A20

P698

Q27005629-1F4A3917-57E9-47DF-8DEB-75384A39A95E

P932

Q27005629-B64826F2-2DDA-4069-B96E-E6105EA01172

P3181

P356

P1433

Pediatric Blood & Cancer

P1476

Novel molecular pathways in Gorham disease: implications for treatment

@en

P2093

David H Ebb

http://www.w3.org/2001/XMLSchema#string

Inne H M Borel Rinkes

http://www.w3.org/2001/XMLSchema#string

Jeroen Hagendoorn

http://www.w3.org/2001/XMLSchema#string

Torunn I Yock

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis

Molecular mechanisms and clinical applications of angiogenesis

Lymphatic imaging in humans with near-infrared fluorescence

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Recurrent hemorrhagic pericardial effusion in a child due to diffuse lymphangiohemangiomatosis: a case report.

Gorham's disease or massive osteolysis.

A case of Gorham's disease with chylothorax treated curatively with radiation therapy.

P304

401-406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3218201

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/PBC.24832

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Timothy P Padera

P577

2013-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258430712

http://www.w3.org/2001/XMLSchema#string

P698

24214028

http://www.w3.org/2001/XMLSchema#string

P932

4123459

http://www.w3.org/2001/XMLSchema#string